Dystrogen Therapeutics

Regenerative Medicine · Cell & Gene Therapy

Overview

Dystrogen Therapeutics is a clinical-stage biotech company developing chimeric cell therapy for muscle wasting disorders such as Duchenne muscular dystrophy (DMD), offering a universal treatment without immunosuppression.

Key facts

These are the key facts about Dystrogen Therapeutics on Alion as of Nov 13, 2026. Dystrogen Therapeutics is headquartered in Chicago, United States. It was founded in 2017. The latest round is Venture - Series Unknown of $1.1M, announced in 2019.

Headquarters
Chicago, United StatesAlion company profile, updated Nov 11, 2026
Founded
2017Alion company profile, updated Nov 11, 2026
Employees
1-10Alion company profile, an estimated range
Total raised
$1.1MSum of 1 equity round Alion knows
Latest round
Venture - Series Unknown · $1.1M · Aug 5, 2019SEC Form D filing · sec.gov
Official records

Funding and backers

Total raised
$1.1M
1 round on record
Latest round
$1.1M
Venture round · Aug 2019 · 7 yr ago
Team
1-10
employees, estimated range
The money's age
Long since its last round
87 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 5, 2019 Raised a round Venture round $1.1M · SEC Form D 2017 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Aug 2019 $1.1M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Dystrogen Therapeutics Corp SEC Form D
Investors in similar startupsfunds that back the companies most like this one
SFC Capital
backs Avigen logo
Kleiner Perkins
backs Arsenal Bio
BGF
backs Cellular Origins
SOSV
backs Tinkeso Therapeutics
ARCH Venture Partners
backs Arsenal Bio
Hitachi Ventures
backs Arsenal Bio
Similar startupsby what they do, their industry and backers
Celaid Therapeutics
セレイドセラピューティクス - 細胞治療(造血幹細胞). Change the futurewith cell therapy.
Cellipont
Advance your cell therapy with Cellipont Bioservices, a leading cell therapy CDMO, offering tailored development, analytics, and cGMP…
Arsenal Bio
Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.
LygenesisVenture round $17.8M · 3 yr ago · Founded 2017 · 51-200 employees
About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's…
Tinkeso TherapeuticsFounded 2017 · 1-10 employees
Is to address the patient unmet needs with our novel off-the-shelf, allogeneic Natural Killer T (NKT) cell therapies for the treatment of…
Shinobi Therapeutics Inc.201-500 employees
Shinobi Therapeutics is transforming cell therapy with scalable, immune-evasive iPSC-derived treatments for cancer and autoimmune diseases.

Financials

Total raised
$1.1M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2019 $1.1M Details

People

Kris Siemionow
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Chicago United States
HQ
1-10 est. staff

How to cite this page

Alion, "Dystrogen Therapeutics: key facts", as of Nov 13, 2026. https://alion.io/company/dystrogen-therapeutics

These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0